NATCO Pharma along with its marketing partner Arrow International (an affiliate of Teva Pharmaceutical Industries), have announced the launch of the first generic version of Revlimid (Lenalidomide capsules) in 5mg, 100mg, 15mg, and 25mg strengths in the U.S. market.

The above strengths of lenalidomide capsules are prescribed in adults for the treatment of (1) multiple myeloma in combination with the medicine dexamethasone, (2) certain myelodysplastic syndromes, and (3) mantle cell lymphoma following specific prior treatment.

NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene (now part of Bristol-Myers Squibb).